Ioannis Papagiannis, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1043484561
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,000 of the $56,097 with a category attached, or 69.5%. Amgen accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2023 at $27,466 and has fallen 57.8% since, to $11,579 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $434.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$56K
- AbbVie$22
Across 2 payments — averaging $591.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$7,05013%
- Speaking & faculty fees$39,00070%
- Travel & lodging$6,98312%
- Food & beverage$3,0545%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$47,406
How this compares
$56,097 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $246,697 |
| TrulicityDulaglutide | 47 | $89,482 |
| JardianceEmpagliflozin | 71 | $80,447 |
| FarxigaDapagliflozin Propanediol | 27 | $29,516 |
| JanuviaSitagliptin Phosphate | 40 | $21,890 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $21,819 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $17,150 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $12,658 |
| Testosterone | 22 | $10,521 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $8,631 |
| SynthroidLevothyroxine Sodium | 82 | $8,175 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $7,188 |
| Novolog FlexpenInsulin Aspart | 16 | $5,012 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $4,851 |
| Levothyroxine Sodium | 288 | $4,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $22 | $8,17582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.